Gedatolisib has been evaluated in a phase I trial in combination with chemotherapy (docetaxel or cisplatin) in NSCLC patients or dacomitinib in EGFR mutant NSCLC patients.91 Toxicity profiles were manageable, and ongoing phase I/II trials are underway. This evidence concerns the gene EGFR and non-small cell lung carcinoma.